Persistent efficacy of live attenuated hepatitis A vaccine (H2-strain) after a mass vaccination program

Chinese Medical Journal

Volumn 118, Issue 22, 2005, Pages 1851-1856

  Zhuang, Fang Cheng ^a   Qian, Wen ^a   Mao, Zi An ^a   Gong, Yue Ping ^b   Jiang, Qi ^c   Jiang, Li Min ^a   Chen, Nian Liang ^a   Chai, Shao Ai ^a   Mao, Jiang Sen ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CDC of Shengsi County   (China)

^c CDC of Jiaojiang City   (China)

Author keywords

Hepatitis A vaccines; Mass vaccination; Persistent efficacy

Indexed keywords

HEPATITIS A VACCINE; LIVE VACCINE; VIRUS ANTIBODY; ZHEPU;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CHILD; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; FEMALE; FOLLOW UP; GEOMETRY; GROUPS BY AGE; HEALTH SURVEY; HEPATITIS A; HEPATITIS A VIRUS; HUMAN; INOCULATION; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MICROPARTICLE ENZYME IMMUNOASSAY; MORBIDITY; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; STATISTICAL SIGNIFICANCE; VIRUS STRAIN; WORLD HEALTH ORGANIZATION;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FOLLOW-UP STUDIES; HEPATITIS A; HEPATITIS A VACCINES; HEPATITIS ANTIBODIES; HUMANS; IMMUNOGLOBULIN G; MASS IMMUNIZATION; VACCINES, ATTENUATED;

EID: 28644433269     PISSN: 03666999     EISSN: 03666999     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Marier R. The reporting of communicable disease. Am J Epidemiol 1977;105:587-590.
2. Mao JS, Dong DX, Zhang HY, et al. Study of attenuated live hepatitis A vaccine (H2 strain) in humans. J Infect Dis 1989;159:621-624.
3. Mao JS, Dong DX, Zhang HY, et al. Development of live attenuated hepatitis A vaccine (H2 strain). Vaccine 1990;8:523-524.
4. The Committee for Standardization of Biologics of the P. R. China. Requirements for Biologics of the People's Republic of China. Beijing: Chemical Industry Press; 2000:83-86.
5. Expert Committee on Biological Standardization, World Health Organization. Texts of requirements for biological Substances. Geneva: WHO, 1990:66-98.
6. Zhang SY, Mao JS, Huang HY, et al. Safety observation of live attenuated hepatitis A vaccine (H2 strain) inoculation to humans. Natl Med J China (Chin) 1990;70:682-684.
7. Mao JS, Chai SA, Xie RY, et al. Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2 strain) in humans. Vaccine 1997;15:944-947.
8. Xu ZY, Wang XY, Li RC, et al. Preliminary results of a randomized and controlled trail of live attenuated hepatitis A vaccine. Chin Med Sci J (Chin) 1999;14 Suppl:8-10.
9. Fields BN, Knipe DM, Howley PM, et al. Fields Virology, 3rd ed. New York: Lippincott-Raven Publishers; 1996: 697-698.
10. Liu Y, Quyan PY, Xu ZY. Quantity assay the anti-HAV using ELISA method. In: Liu XG, ed. Laboratory diagnostics of viral hepatitis, 2nd ed. Bejing: People's Medical Publishing House; 1999:355-357.
11. Midthun K, Ellerbeck E, Gershmen K, et al. Safety and immunogencity of a live attenuated hepatitis A virus vaccine in seronegative volunteers. J Infect Dis 1991; 163:735-739.
12. Zhuang FC, Jian Q, Gong YP, et al. Epidemilogical efficacy of live attenuated hepatitis A vaccine (H2 strain): results after 10 years observation. Chin J Epidemiol (Chin) 2001;22:188-190.
13. Jiang SP, Huang QC, Chen JM, et al. A large scale efficacy trail of live attenuated hepatitis A vaccine in Liuzhou. Chin J Epidemiol (Chin) 1995;16:140-142.
14. Havens WP Jr, Marck RE. The leukocytic response of patient with experimentally induced infectious hepatitis. Am J Med Sci 1946;212:129-138.
15. Dienstage JL, Poper H, Purcell RH. The pathology of viral hepatitis types A and B in chimpanzees. Am J Pathol 1976;83:131-148.
16. Gust ID, Lehmann NI, Dimitrakakis M. A seroepidemiologyic study of antibody to hepatitis A antigen and age: a cohort effect? J Infect Dis 1978; 138:425-426.
17. Iwarson S, Frosner G, Lindholm A, et al. The changed epidemiology of hepatitis A infection in Scandinavia. Scand J Infect Dis 1978;10:155-156.
18. Szmuness W, Dienstage JL, Purcell RH, et al. Distribution of antibody to hepatitis A antigen in urban adults populations. N Engl J Med 1976;295:755-759.
19. Wang XY, Xu ZY, Yao X, et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactive hepatitis A vaccines. Vaccine 2004;22:1941-1945.
20. Zao YL, Meng ZD, Xu ZY, et al. H2 strain live attenuated hepatitis A vaccine: protective efficacy in a hepatitis A outbreak. World J Gastroenterol 2000;6: 829-832.